License Royalties Sample Clauses
License Royalties. 5.2.1 In consideration of the rights and licence granted to Acorda to the Elan Patent Rights by virtue of the SCI Agreement, Acorda has paid to Elan $5,000,000 (five million United States Dollars); and
5.2.2 In consideration of the rights and licence granted to MS R & D to the Elan Patent Rights by virtue of the MS Agreement, MS R & D has paid to Elan $15,000,000 (fifteen million United States Dollars) – receipt of each of which is hereby acknowledged by Elan.
License Royalties. 3.1 In partial consideration for the license granted by STANFORD to RIGEL under Section 2.1, RIGEL agrees to pay to STANFORD the following:
(a) An initial, nonrefundable license issue royalty of [ * ], which amount shall be paid within thirty (30) days after the Effective Date.
(b) A royalty payment equal to [ * ] on each of the first three (3) anniversaries of the Effective Date. After the third (3rd) anniversary of the Effective Date, the sublicense shall be considered perpetual and fully paid-up.
License Royalties. 1. In consideration of the rights and license granted to IOMED to the DDS IONTOPHORETIC PATENT RIGHTS by virtue of this Agreement, IOMED shall pay to DDS, the sum of **** United States Dollars **** in cash by wire transfer due upon execution of this Agreement and payable within two business days of the EFFECTIVE DATE.
License Royalties. 1. In consideration of the rights and license granted to IOMED to the ELAN IONTOPHORETIC PATENT RIGHTS by virtue of this Agreement, IOMED shall pay to ELAN, the sum of (****) United States Dollars (****) in cash by wire transfer due upon execution of this Agreement and payable within two business days of the EFFECTIVE DATE.
License Royalties. 3.1 In partial consideration for the license granted by STANFORD to RIGEL under Section 2.1, RIGEL agrees to pay to STANFORD the following:
(a) An initial, nonrefundable license issue royalty of [ * ], which amount shall be paid within thirty (30) days after the Effective Date.
(b) A royalty payment equal to [ * ] on each of the first three (3) anniversaries of the Effective Date. After the third (3rd) anniversary of the Effective Date, the sublicense shall be considered perpetual and fully paid-up.
3.2 If RIGEL grants to Cell Genesys a sublicense under the Licensed Biological Materials to use and sell products in the field of human and/or animal gene therapy, RIGEL shall pay to STANFORD during the term of such sublicense a sublicense fee as follows: Upon signing of the sublicense $ [ * ] On each of the first three (3) anniversaries of the effective date of such sublicense $ [ * ] On the 4th, 5th and 6th anniversaries of the effective date of such sublicense $ [ * ] After the sixth (6th) anniversary of the effective date of such sublicense, the sublicense shall be considered perpetual and fully paid-up.
License Royalties. 7.1.1 In consideration of the license of the ELAN PATENTS granted to GEMINI under this Agreement, GEMINI shall pay to ELAN
(i) the sum of $7,500,000 due upon execution of this Agreement and payable within 2 business days of the EFFECTIVE DATE; and
(ii) a license royalty fee of [omitted] of NET INCOME until the aggregate of such royalty fee equals [omitted].
7.1.2 Payment of the license fee royalty pursuant to Clause 7.1.1
License Royalties. In consideration for Licensor’s granting of the license granted under Section 2.1, Licensee shall pay Licensor a perpetual license royalty as follows:
(a) 5% of the per barrel spot price of West Texas Intermediate (averaged over the quarter) for each barrel of oil produced post-processing using the Technology in the Territory by Licensee; and
(b) 5% of the per barrel spot price of West Texas Intermediate (averaged over the quarter) for each barrel of oil produced post-processing using the Technology in the Territory by Sublicensee.
License Royalties. 5.2.1 In consideration of the rights and licence granted to Acorda to the Elan Patent Rights by virtue of the SCI Agreement, Acorda has paid to Elan $[****]; and
5.2.2 In consideration of the rights and licence granted to MS R & D to the Elan Patent Rights by virtue of the MS Agreement, MS R & D has paid to Elan $[****] – receipt of each of which is hereby acknowledged by Elan.
License Royalties. 6.1 At S3's discretion, S3 may license Intellon's patent claims that are necessary to implement chipsets complying with the HomePlug 1.X Specifications **********. In addition, S3 may license Intellon's Technology embodied in the Chipset that is licensable at no additional cost to Intellon for a specific field of use **********. Nothing in this Agreement will limit S3 from developing, licensing or manufacturing its own chipsets.
License Royalties. (a) Hologic hereby grants, and shall cause any Hologic Affiliate that owns or has the right to license any Hologic Patent to hereby grant, to Conceptus, Conceptus Affiliates, Conceptus Contractors and Conceptus Customers an irrevocable, world-wide, royalty-bearing, nonsublicenseable, non-transferable (except in accordance with Section 8.2) and non-exclusive license under the Hologic Patents in the PBC Field: (i) to make, have made, use, sell, offer to sell, practice, lease, keep, import, have imported, export, have exported, distribute (including through multiple channels of distribution), commercially exploit or otherwise dispose of Conceptus Products and Services; and (ii) to practice any method or process claimed in the Hologic Patents for purposes of effectuating the license granted in clause (i) of this Section 4.2(a).
(b) For each Royalty-Bearing Product Sold by or on behalf of Conceptus in the United States after the Effective Date and until the earlier of the expiration of the last-to-expire of the Hologic Patents or the termination by Conceptus of the License as set forth in Article VII, Conceptus shall pay to Hologic an amount equal to five percent (5%) of the actual selling price (i.e. revenue received per unit sold) of such Royalty-Bearing Product (each such per unit amount a “Royalty” and collectively, the “Royalties”).
(c) Conceptus shall pay all Royalties owed to Hologic for Royalty-Bearing Products Sold by or on behalf of Conceptus in each calendar quarter within forty-five (45) days following the end of such calendar quarter. All Royalties shall be paid by Conceptus in U.S. dollars. A Royalty-Bearing Product is “Sold by or on behalf of Conceptus” under this Agreement upon first transfer pursuant to the license granted in Section 4.2(a). Internal sales to Conceptus Affiliates (e.g. for transfer pricing) do not qualify as being Sold by or on behalf of Conceptus hereunder. A Conceptus Product and Service that is distributed for internal research purposes within Conceptus, or that is made available for clinical or preclinical research or trials, is not a Royalty-Bearing Product and is not considered Sold by or on behalf of Conceptus, even if such product otherwise satisfies the definition of a Royalty-Bearing Product under this Agreement.
(d) Following the termination or expiration of this Agreement or the License as set forth in Article VII, Hologic retains the right to collect from Conceptus any Royalties earned but not paid prior to such te...